296 related articles for article (PubMed ID: 35511419)
1. Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.
Aykul S; Huang L; Wang L; Das NM; Reisman S; Ray Y; Zhang Q; Rothman N; Nannuru KC; Kamat V; Brydges S; Troncone L; Johnsen L; Yu PB; Fazio S; Lees-Shepard J; Schutz K; Murphy AJ; Economides AN; Idone V; Hatsell SJ
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35511419
[TBL] [Abstract][Full Text] [Related]
2. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
3. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
[TBL] [Abstract][Full Text] [Related]
5. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
6. An anti-ACVR1 antibody exacerbates heterotopic ossification by fibro-adipogenic progenitors in fibrodysplasia ossificans progressiva mice.
Lees-Shepard JB; Stoessel SJ; Chandler JT; Bouchard K; Bento P; Apuzzo LN; Devarakonda PM; Hunter JW; Goldhamer DJ
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35503416
[TBL] [Abstract][Full Text] [Related]
7. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.
Srinivasan D; Arostegui M; Goebel EJ; Hart KN; Aykul S; Lees-Shepard JB; Idone V; Hatsell SJ; Economides AN
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254701
[TBL] [Abstract][Full Text] [Related]
8. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
[TBL] [Abstract][Full Text] [Related]
9. Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.
Collins MT
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703179
[TBL] [Abstract][Full Text] [Related]
10. TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva.
de Ruiter RD; Wisse LE; Schoenmaker T; Yaqub M; Sánchez-Duffhues G; Eekhoff EMW; Micha D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768622
[TBL] [Abstract][Full Text] [Related]
11. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Shore EM
Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
[TBL] [Abstract][Full Text] [Related]
12. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
13. Activin A does not drive post-traumatic heterotopic ossification.
Hwang C; Pagani CA; Das N; Marini S; Huber AK; Xie L; Jimenez J; Brydges S; Lim WK; Nannuru KC; Murphy AJ; Economides AN; Hatsell SJ; Levi B
Bone; 2020 Sep; 138():115473. PubMed ID: 32553795
[TBL] [Abstract][Full Text] [Related]
14. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.
Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC
J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499
[TBL] [Abstract][Full Text] [Related]
15. Variable signaling activity by FOP ACVR1 mutations.
Haupt J; Xu M; Shore EM
Bone; 2018 Apr; 109():232-240. PubMed ID: 29097342
[TBL] [Abstract][Full Text] [Related]
16. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
[TBL] [Abstract][Full Text] [Related]
17. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva.
Towler OW; Shore EM; Kaplan FS
Bone; 2020 Jan; 130():115116. PubMed ID: 31655222
[TBL] [Abstract][Full Text] [Related]
18. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
[TBL] [Abstract][Full Text] [Related]
20. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
